ArticlePharmaceutical research1996
Effects of permeation enhancers on the transport of a peptidomimetic thrombin inhibitor (CRC 220) in a human intestinal cell line (Caco-2).
Article in Pharmaceutical research, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 37 citations in OpenAlex.
- Prodrug approach for alphaIIbbeta3-peptidomimetic antagonists to enhance their transport in monolayers of a human intestinal cell line (Caco-2): comparison of in vitro and in vivo data.Pharmaceutical research · 1999Article
- Influence of different calcic antagonists on the Caco-2 cell monolayer integrity or "TEER, a measurement of toxicity?".European journal of drug metabolism and pharmacokineticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe effects of five different permeation enhancer systems on the transport properties of a peptidomimetic thrombin inhibitor. CRC 220, were investigated in monolayers of a human intestinal cell line (Caco-2).
methodsThe transepithelial transport rates and additionally the cytotoxic properties of these enhancers were characterized using the following tests: measurement of the transepithelial electrical resistance (TEER), the MTT-transformation, the protein content and the release of cytosolic lactate dehydrogenase (LDH), as well as FITC-phalloidin and propidium iodide staining.
resultsAll permeation enhancer systems showed concentration-dependent effects on cell permeability and toxicity. The most prominent effects on peptide transport were seen at the highest concentration (40 mM), yielding the rank order, NaTC > NaTC/Cholesterol > Solulan C24 > NaTC/Oleic acid > NaTC/PC18. Using the TEER after 120 min exposure as the most sensitive parameter describing cytotoxicity, the following order was obtained: Solulan C24 > NaTC > NaTC/PC18 = NaTC/Cholesterol > NaTC/Oleic acid > NaTC/PC. Generally, efficient enhancement of peptide transport was associated with a noticeable influence on cell viability under in-vitro conditions.
conclusionsTaking into account permeation and cytotoxicity as a function of concentration, both NaTC at 15 mM and the mixed micellar system NaTC/oleic acid at 0.75 mM offer interesting enhancement properties, showing an 18-fold increase in CRC 220 transport rates. The effects on cell viability and cytotoxicity were comparatively low and of reversible nature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.